WD-1603
Asset
Extended-release carbidopa-levodopa formulation restoring dopamine levels in the brain.
- Stage
- Phase 2
- Modality
- Small molecule
- Target
- Ddc
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Parkinson's disease
Phase 2, Completed, NCT05036473, clinicaltrials.gov, 8 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Evidence for its targets1
- Competitors12
- Signals1
Every asset’s record: target, stage, trials and the evidence behind it.